Cargando…
Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial
BACKGROUND: Mucositis and dysphagia are common adverse effects of radiotherapy (RT) treatment of locally advanced squamous cell cancer of the head and neck (LA-SCCHN). Chemotherapy added to RT increases survival rates but causes worse mucositis and dysphagia. The aim of this analysis was to assess t...
Autores principales: | Bonner, James A., Giralt, Jordi, Harari, Paul M., Baselga, Jose, Spencer, Sharon, Bell, Diana, Raben, David, Liu, Joyce, Schulten, Jeltje, Ang, Kian K., Rosenthal, David I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027878/ https://www.ncbi.nlm.nih.gov/pubmed/27323346 http://dx.doi.org/10.1016/j.ejca.2016.05.008 |
Ejemplares similares
-
p16, HPV, and Cetuximab: What Is the Evidence?
por: Bonner, James A., et al.
Publicado: (2017) -
Observational, prospective, phase 4 study in patients with first‐line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum‐based therapy: DIRECT
por: Guigay, Joël, et al.
Publicado: (2021) -
First‐line cetuximab + platinum‐based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real‐world observational study—ENCORE
por: Le Tourneau, Christophe, et al.
Publicado: (2023) -
Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 Inhibition
por: Bonner, James A., et al.
Publicado: (2015) -
Dysphagia in Frail Patients Is Not Frailty Dysphagia
por: Smithard, David G.
Publicado: (2018)